# HOPU Investment Management Company

> HOPU Investment Management Company is a VC fund backing Biotechnology. See 32 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Xicheng, China
- Total investments: 32
- Last investment: Mar 2025
- Lead investor: 38%
- Fund size: $2B
- Last fund: Feb 2018
- Last updated: Aug 2026

HOPU Investment Management Company is a VC fund in Xicheng focused on Biotechnology and Artificial Intelligence. HOPU Jinghua (Beijing) Investment Management Company Limited is a private equity investment firm formed in 2008 by former Goldman Sachs China partner Fang Fenglei, former Goldman Sachs Co-Head of Investment Banking (excluding Japan) Richard Ong, and former KPMG Chair Dominic Ho. It raised its first fund in 2008 and went on hiatus in 2011. In 2013,HOPU re-entered the private equities market and raised a new fund with plans to expand even more.

## Contacts

5 contacts available for HOPU Investment Management Company. Shizune tracks 1 team members at HOPU Investment Management Company. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hopu-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 22% |
| Artificial Intelligence | 7 | 22% |
| Health Care | 4 | 13% |
| Pharmaceutical | 4 | 13% |
| Internet | 3 | 9% |

58 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 8 | 25% |
| Series C | 7 | 22% |
| Private Equity | 4 | 13% |
| Series A | 2 | 6% |
| Series B | 2 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 19 | 59% |
| United States | 4 | 13% |
| France | 1 | 3% |
| Singapore | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fenglei Fang | Founding Partner & Chairman | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ceva Santé Animale | Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs. |  | Private Equity | Mar 31, 2025 |  |
| JingXi ZhiXing | Jingxi Zhixing is a supplier of vehicle chassis suspension and brake systems. | $280.9M | Series A | Jun 15, 2023 |  |
| COFCO | COFCO is the largest supplier of diversified products and services in the agricultural products and food industry in China. It is devoted to utilizing renewable natural resources to provide healthy and nutritious food, high quality lifestyle and services, as well as contributing to improve people’s living standards, social prosperity and stability.COFCO plays a pivotal role as a bridge in the markets of edible oils and foodstuff between China and the world, and serves as the main importing and exporting channel for bulk agricultural products such as wheat, corn, rice and sugar. As an investment holding company specialized in trade and processing of oil and foodstuff as well as other businesses, COFCO continuously strives to upgrade its oil and foodstuff chains, which include those of oils and oilseeds, corn, wheat, rice, wine, tomatoes, dairy products, meat, barley, tea, chocolate and various other products. In light of China's economic growth, return on shareholders’ value and available business resources, COFCO is also involved in the development of real estate, hotels, non-grain bio-energy, packaging, finance and other industries. | $3.1B | Post-IPO Equity | Feb 02, 2023 |  |
| COFCO Fortune | COFCO Fortune provides high-quality food to customers through a fully integrated value chain with many well-known retailers and other state-owned enterprises. | $779.6M | Private Equity | Jan 16, 2023 |  |
| Iluvatar CoreX | Iluvatar CoreX is a leading developer of high-performance computing solutions including System-on-a-Chip (SoC) chipset and its proprietary software platform. The company was founded in December 2015 by a group of world-class software and semiconductor experts from Silicon Valley and China which have been working together for more than two decadesin the field of AI at companies like Oracle, AMD/ATI and Fujitsu.Iluvatar has assembled a group of experts in system software, computing middleware, algorithms, parallel processing, GPU, AI, and IC design to develop end-to-end high-performance processing solutions in-house. Iluvatar solution addresses the limitations on computing power needs for AI applications by creatively exploiting the advantages of ultra-large-scale parallel computing architecture, with its general-purpose, standard, and high-performance cloud computing SoC solution (GP-GPU). Iluvatar solution is already proven. For the last 3 years, the company has been shipping its new generation of data processing software technology (soft silicon) named SkyDiscovery. | $148.8M | Series C | Jul 13, 2022 |  |
| Laiye | Laiye is a digital workforce platform that empowers organizations by integrating AI Agents to boost employee productivity and creativity. The platform combines various intelligent automation capabilities, including RPA and IDP, to streamline operations and enhance business outcomes. | $70M | Series C | Apr 18, 2022 |  |
| Laiye | Laiye is a digital workforce platform that empowers organizations by integrating AI Agents to boost employee productivity and creativity. The platform combines various intelligent automation capabilities, including RPA and IDP, to streamline operations and enhance business outcomes. | $70M | Series C | Apr 18, 2022 |  |
| XtalPi | XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies. | $400M | Series D | Aug 11, 2021 |  |
| Lyndra Therapeutics | Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs. | $60.5M | Series C | Jun 24, 2021 |  |
| Shumei Technology | Shumei Technology is an information technology company that provides an AI-based business risk control for companies and organizations. It specializes in SaaS, AI-based risk control service network, data-driven products, and bigdata. The company was founded in 2015 and headquartered in Wangjing, Beijing, China. | $135M | Series D | Apr 21, 2021 |  |

10 of 32 investments shown.

## Co-investors
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 5 deals together
- [Temasek](https://shizune.co/investors/profile/temasek) — VC Fund, 5 deals together
- [Boyu Capital](https://shizune.co/investors/profile/boyu-capital) — VC Fund, 4 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 4 deals together
- HOPU Investment — VC Fund, 3 deals together
- [5Y Capital](https://shizune.co/investors/profile/morningsidevc) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does HOPU Investment Management Company invest in?

HOPU Investment Management Company invests primarily in Biotechnology, Artificial Intelligence and Health Care startups, most often at Series D and Series C stage. Most of the 32 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact HOPU Investment Management Company?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HOPU Investment Management Company?

The team at HOPU Investment Management Company includes Fenglei Fang (Founding Partner & Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co